CalciMedica, Inc. (CALC) Stock Ticker
Market factors today
Unlock the full CALC picture
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CALC stock facts
| Ticker symbol | CALC |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $5.5M |
| CEO | A. Rachel Leheny |
| Employees | 15 |
| Headquarters | La Jolla, CA, US |
| IPO date | 2023-06-14 |
| Website | www.calcimedica.com |
What you can see for CALC on Tickr
Live CALC price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CALC report.
Rankings
FAQ
What is the ticker symbol for CalciMedica, Inc.?
The ticker symbol for CalciMedica, Inc. is CALC, listed on the NASDAQ Capital Market.
What is CALC?
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and…